NASDAQ:LPCN - Lipocine Stock Price, Forecast & News

Lipocine trades on the NASDAQ under the ticker symbol "LPCN."

Lipocine Inc (NASDAQ:LPCN) issued its earnings results on Tuesday, November, 12th. The specialty pharmaceutical company reported ($0.12) EPS for the quarter, topping analysts' consensus estimates of ($0.16) by $0.04. The specialty pharmaceutical company earned $0.17 million during the quarter. View Lipocine's Earnings History.

Lipocine is scheduled to release their next quarterly earnings announcement on Wednesday, March 4th 2020. View Earnings Estimates for Lipocine.

2 equities research analysts have issued 12-month price targets for Lipocine's stock. Their forecasts range from $2.00 to $2.00. On average, they anticipate Lipocine's share price to reach $2.00 in the next twelve months. This suggests a possible upside of 468.2% from the stock's current price. View Analyst Price Targets for Lipocine.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Lipocine in the last year. There are currently 2 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Lipocine.

Media stories about LPCN stock have trended extremely negative recently, according to InfoTrie Sentiment Analysis. InfoTrie identifies negative and positive press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Lipocine earned a media sentiment score of -4.0 on InfoTrie's scale. They also assigned media headlines about the specialty pharmaceutical company a news buzz of 3.0 out of 10, indicating that recent press coverage is unlikely to have an impact on the company's share price in the near term. View News Stories for Lipocine.

Lipocine saw a increase in short interest during the month of November. As of November 15th, there was short interest totalling 231,300 shares, an increase of 53.9% from the October 31st total of 150,300 shares. Based on an average daily volume of 306,800 shares, the days-to-cover ratio is presently 0.8 days. Approximately 1.0% of the company's stock are sold short. View Lipocine's Current Options Chain.

Some companies that are related to Lipocine include Celsion (CLSN), DiaMedica Therapeutics (DMAC), Edesa Biotech (EDSA), Sunesis Pharmaceuticals (SNSS), Teligent (TLGT), Seelos Therapeutics (SEEL), Adamis Pharmaceuticals (ADMP), Zafgen (ZFGN), OTCMKTS:EMBI (EMBI), Akari Therapeutics (AKTX), Jaguar Health (JAGX), VIVUS (VVUS), Addex Therapeutics (ADDXF), Nemus Bioscience (NMUS) and Sernova (SEOVF).

Based on aggregate information from My MarketBeat watchlists, some companies that other Lipocine investors own include Synergy Pharmaceuticals (SGYP), Flexion Therapeutics (FLXN), Omeros (OMER), Novavax (NVAX), Cara Therapeutics (CARA), Melinta Therapeutics (MLNT), Progenics Pharmaceuticals (PGNX), SCYNEXIS (SCYX), Actinium Pharmaceuticals (ATNM) and Protalix Biotherapeutics (PLX).

Lipocine's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Millennium Management LLC (0.09%). Company insiders that own Lipocine stock include Gregory Brooks Bass, Jeffrey Arvin Fink, Mahesh V Patel, Morgan R Brown and Stephen A Hill. View Institutional Ownership Trends for Lipocine.

LPCN stock was purchased by a variety of institutional investors in the last quarter, including Millennium Management LLC. View Insider Buying and Selling for Lipocine.

Shares of LPCN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of LPCN stock can currently be purchased for approximately $0.35.

Lipocine has a market capitalization of $8.94 million and generates $430,000.00 in revenue each year. The specialty pharmaceutical company earns $-11,660,000.00 in net income (profit) each year or ($0.55) on an earnings per share basis. Lipocine employs 10 workers across the globe.View Additional Information About Lipocine.

The official website for Lipocine is http://www.lipocine.com/.

Lipocine's mailing address is 675 ARAPEEN DRIVE SUITE 202, SALT LAKE CITY X1, 84108. The specialty pharmaceutical company can be reached via phone at 801-994-7383 or via email at [email protected]